Skip to content

US · TBPH · BIOTECHNOLOGY

Theravance Biopharma Inc (TBPH) intrinsic value and stock valuation

$17.03as of 2026-11-21 · Mkt cap 875.9M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Theravance Biopharma Inc DCF and intrinsic value

InvestorsCraft values TBPH with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TBPH’s statements →

Theravance Biopharma Inc Graham Number

Graham Number: $16.71d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 theravance.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$107.5M+8.4% 5y CAGRd
20112025
Net income
$105.9M
20112025
Free cash flow
$238.5M
20112025
Total equity
$296.7M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$107.5M$64.4M$57.4M$51.4M$55.3M
Operating income-$-13.25M-$-46.95M-$-56.03M-$-91.96M-$-257.78M
Net income$105.9M-$-56.42M-$-55.19M$872.1M-$-199.43M
EPSd$2.06M-$-1.15M-$-998.01K$11.9M-$-2.87M
Operating cash flow$238.5M-$-11.54M-$-27M-$-186.99M-$-207.86M
Capital expenditure-$-40K-$-330K-$-2.49M-$-570K-$-3.41M
Free cash flow$238.5M-$-11.87M-$-29.48M-$-187.56M-$-211.26M
Total assets$485.6M$354.2M$382M$607.4M$374.8M
Total debt$75.5M$49.8M$49.2M$52.2M$669.5M
Net debt-$-92.31M$12M$9.61M-$-246.01M$579.6M
Total equity$296.7M$175.5M$213M$441.8M-$-338.57M
Cash and short-term investments$315.4M$88.4M$102.4M$327.5M$173.5M
Income statement
20252024202320222021
Revenue$107.5M$64.4M$57.4M$51.4M$55.3M
Cost of revenue$5.51M$37.6M$40.6M$63.4M$193.7M
Gross profit$102M$26.7M$16.8M-$-12.05M-$-138.35M
Research and development expenses$37.4M$38.1M$46.3M$70.1M$201.6M
Selling, general and administrative expenses$73.7M$69.2M$70.5M$67.1M$99.3M
Other expenses$4.13M-$-33.54M-$-43.96M-$-57.24M-$-181.41M
Operating expenses$115.2M$73.7M$72.8M$79.9M$119.4M
Cost and expenses$120.7M$111.3M$113.5M$143.3M$313.1M
Interest income$0.00$4.88M$9.12M$8.54M$1.11M
Interest expense$2.46M$2.55M$2.35M$6.37M$8.55M
Depreciation and amortization$5.51M$3.62M$2M$3.04M$4.81M
Ebitda$137.2M-$-38.45M-$-51.65M-$-76.08M-$-232.83M
Operating income-$-13.25M-$-46.95M-$-56.03M-$-91.96M-$-257.78M
Total other income/expenses, net$142.5M$2.33M$6.77M-$-860K-$-7.44M
Income before tax$129.3M-$-44.61M-$-49.27M-$-92.81M-$-265.22M
Income tax expense$23.4M$11.8M$5.92M$10K-$-150K
Net income$105.9M-$-56.42M-$-55.19M$872.1M-$-199.43M
Weighted average shares outstanding$50.3M$48.9M$55.3M$73.6M$69.5M
Weighted average diluted shares outstanding$51.5M$48.9M$55.3M$73.6M$69.5M
Balance sheet
20252024202320222021
Cash and short-term investments$315.4M$88.4M$102.4M$327.5M$173.5M
Net receivables$95.5M$68.4M$17.5M$16.8M$57.6M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$418.5M$161.1M$133.5M$353.5M$249.9M
Property, plant and equipment, net$30.3M$35.8M$45.4M$52M$53.4M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$14.4M$0.00$0.00$0.00$68.4M
Total non-current assets$67.1M$193.1M$248.5M$253.9M$125M
Total assets$485.6M$354.2M$382M$607.4M$374.8M
Accounts payable$2.57M$2.24M$1.52M$1.55M$3.1M
Short-term debt$11M$10.7M$3.92M$6.75M$17.4M
Deferred revenue$0.00$0.00$0.00$20K$100K
Total current liabilities$38.3M$32.1M$24.8M$28.7M$58.6M
Long-term debt$64.6M$39.1M$45.2M$45.4M$652.1M
Deferred revenue, non-current$0.00$0.00$0.00$190K$310K
Total non-current liabilities$150.5M$146.5M$144.2M$136.9M$654.8M
Capital lease obligations$31.8M$49.8M$49.2M$52.2M$52.7M
Total liabilities$188.9M$178.6M$169M$165.6M$713.4M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-859.63M-$-965.52M-$-909.1M-$-853.91M-$-1.73B
Accumulated other comprehensive income (loss)$60K$10K-$-60K-$-10K-$0.00
Total equity$296.7M$175.5M$213M$441.8M-$-338.57M
Total investments$161.9M$50.6M$62.9M$29.3M$151.9M
Total debt$75.5M$49.8M$49.2M$52.2M$669.5M
Net debt-$-92.31M$12M$9.61M-$-246.01M$579.6M
Cash flow statement
20252024202320222021
Net income$105.9M-$-56.42M-$-55.19M-$-92.82M-$-265.07M
Depreciation and amortization$5.64M$3.62M$4.26M$7.02M$8.6M
Stock-based compensation$18.5M$21.4M$25.4M$39.7M$62.1M
Change in working capital$120.5M$20.4M-$-8.34M$42.4M-$-39.55M
Accounts receivable-$-27.1M-$-970K-$-690K-$-2.72M$1.8M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$330K$750K$10K-$-1.61M-$-3.53M
Net cash provided by operating activities$238.5M-$-11.54M-$-27M-$-186.99M-$-207.86M
Investments in property, plant and equipment-$-40K-$-330K-$-2.49M-$-570K-$-3.41M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-105.28M$12.3M-$-32.7M$1.15B$124.5M
Common stock issued$790K$100K$0.00$0.00$108.2M
Common stock repurchased-$-4.03M-$-3.1M-$-199.55M-$-132.28M-$-9.06M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-3.25M-$-2.5M-$-198.93M-$-758.81M$91.9M
Net change in cash$130M-$-1.75M-$-258.63M$208.2M$8.5M
Cash at end of period$168.6M$38.6M$40.4M$299M$90.8M
Operating cash flow$238.5M-$-11.54M-$-27M-$-186.99M-$-207.86M
Capital expenditure-$-40K-$-330K-$-2.49M-$-570K-$-3.41M
Free cash flow$238.5M-$-11.87M-$-29.48M-$-187.56M-$-211.26M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Theravance Biopharma Inc

        Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

        CEO
        Rick E. Winningham
        Employees
        90
        Beta
        0.17

        Explore

        Frequently asked questions

        What is the intrinsic value of Theravance Biopharma Inc (TBPH)?

        InvestorsCraft does not currently publish an intrinsic value for TBPH. How the IC value is calculated.

        Is TBPH undervalued?

        InvestorsCraft does not publish an undervaluation signal for TBPH at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.